Last reviewed 2026-04-22 · How we verify

Insulin Actrapid

Insulin Actrapid is a rapid-acting insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.

Insulin Actrapid is a rapid-acting insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Mechanism of action

Actrapid is a soluble (regular) human insulin formulation that mimics the body's natural insulin secretion in response to meals. It binds to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. This rapid-acting formulation is typically used in combination with longer-acting insulins or as a bolus therapy with meals.

Approved indications

• Type 1 diabetes mellitus
• Type 2 diabetes mellitus

Common side effects

• Hypoglycemia
• Weight gain
• Injection site reactions
• Lipodystrophy

Key clinical trials

• Text Message for Adolescents With Poorly Controlled Type 1 Diabetes (NA)
• Epigenetic Regulation of Human Adipose Tissue Distribution (NA)
• Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
• Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity (PHASE2)
• Risk Assessment of Pancreatic Islet Autoimmunity in Patients With AITD
• Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise (NA)
• Critical Food Ingredients on Immunocompetence to Prevent the Risk and Development of Obesity/Metabolic Syndrome (NA)
• Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.